High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas

Oral Oncology

Volumn 45, Issue 1, 2009, Pages 39-46

  Kidani, Kazunori ^a,b   Osaki, Mitsuhiko ^a,c   Tamura, Takayuki ^a   Yamaga, Kensaku ^a   Shomori, Kohei ^a   Ryoke, Kazuo ^b   Ito, Hisao ^a  

^a TOTTORI UNIVERSITY   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

^c TOTTORI UNIVERSITY   (Japan)

Author keywords

Apoptosis; EZH2; Ki 67; Oral squamous cell carcinoma; P53; Prognosis

Indexed keywords

BIOLOGICAL MARKER; KI 67 ANTIGEN; PROTEIN ENHANCER OF ZESTE HOMOLOG 2; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CARCINOGENESIS; CONTROLLED STUDY; DYSPLASIA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOUTH CARCINOMA; MOUTH MUCOSA; ORAL SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TUMOR DIFFERENTIATION; TUMOR GROWTH; TUMOR VOLUME;

AGED; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MOUTH MUCOSA; MOUTH NEOPLASMS; PROGNOSIS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 57549115637     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2008.03.016     Document Type: Article

References (38)

1. Sakai E., Rikimaru K., Ueda M., Matsumoto Y., Ishii N., Enomoto S., et al. The p53 tumor-suppressor gene and ras oncogene mutations in oral squamous-cell carcinoma. Int J Cancer 52 (1992) 867-872
2. Momose F., Araida T., Negishi A., Ichijo H., Shioda S., and Sasaki S. Variant sublines with different metastatic potentials selected in nude mice from human oral squamous cell carcinomas. J Oral Pathol Med 18 (1989) 391-395
3. Cohen E.E., Lingen M.W., and Vokes E.E. The expanding role of systemic therapy in head and neck cancer. J Clin Oncol 22 (2004) 1743-1752
4. Cooper J.S., Pajak T.F., Forastiere A.A., Jacobs J., Campbell B.H., Saxman S.B., et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. New Engl J Med 350 (2004) 1937-1944
5. Banoczy J., and Csiba A. Occurrence of epithelial dysplasia in oral leukoplakia, analysis and follow-up study of 12 cases. Oral Surg Oral Med Oral Pathol 42 (1976) 766-774
6. Silverman Jr. S., Gorsky M., and Lozada F. Oral leukoplakia and malignant transformation: a follow-up study of 257 patients. Cancer 53 (1984) 563-568
7. Lumerman H., Freedman P., and Kerpel S. Oral epithelial dysplasia and the development of invasive squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 79 (1995) 321-329
8. Kodani I., Shomori K., Osaki M., Kuratate I., Ryoke K., and Ito H. Expression of minichromosome maintenance 2 (MCM2), Ki-67, and cell-cycle-related molecules, and apoptosis in the normal-dysplasia-carcinoma sequence of the oral mucosa. Pathobiology 69 (2001) 150-158
9. Shibata M., Kodani I., Osaki M., Araki K., Adachi H., Ryouke K., et al. Cyclo-oxygenase-1 and -2 expression in human oral mucosa, dysplasias and squamous cell carcinomas and their pathological significance. Oral Oncol 41 (2005) 304-312
10. Schliephake H. Prognostic relevance of molecular markers of oral cancer - a review. Int J Oral Maxillofac Surg 32 (2003) 233-245
11. Lo Muzio L., Santarelli A., Panzarella V., Campisi G., Carella M., Ciavarella D., et al. Oral squamous cell carcinoma and biological markers: an update on the molecules mainly involved in oral carcinogenesis. Minerva Stomatol 56 (2007) 341-347
12. Kudo Y., Takata T., Ogawa I., Sato S., and Nikai H. Expression of p53 and p21CIP1/WAF1 proteins in oral epithelial dysplasias and squamous cell carcinomas. Oncol Res 6 (1999) 539-545
13. Myoung H., Kim M.J., Lee J.H., Ok Y.J., Paeng J.Y., and Yun P.Y. Correlation of proliferative markers (Ki-67 and PCNA) with survival and lymph node metastasis in oral squamous cell carcinoma: a clinical and histopathological analysis of 113 patients. Int J Oral Maxillofac Surg 35 (2006) 1005-1010
14. Mao C., Lu Y., Lai Q., Xia Y., and Yang C. Expression of p53 gene in oral squamous cell carcinoma and its relation with clinical and pathological parameters and prognosis of patients. Chin Med Sci J 10 (1995) 199-203
15. Gonzalez-Moles M.A., Galindo P., Gutierrez-Fernandez J., Sanches-Fernandes E., Rodriguez-Archilla A., Ruitz-Avila I., et al. P53 protein expression in oral squamous cell carcinoma. survival analysis. Anticancer Res 21 (2001) 2889-2894
16. Gonzalez-Moles M.A., Caballero R., Rodriguez-Archilla A., Ruiz-Avila I., and Bravo I. Prognosis value of the expression of Ki-67 for squamous cell carcinoma of the oral cavity. Acta Stomatol Belg 93 (1996) 159-165
17. Piffko J., Bankfalvi A., Ofner D., Kusch F., Bocker W., Joos U., et al. In situ assessment of cell proliferation at the invasive front of oral squamous cell carcinomas. Virchows Arch 429 (1996) 229-234
18. Simon J.A., and Tamkun J.W. Programming off and on states in chromatin: mechanisms of polycomb and trithorax group complexes. Curr Opin Genet Dev 12 (2002) 210-218
19. Cao R., Wang L., Wang H., Xia L., Erdjument-Bromage H., Tempst P., et al. Role of histone H3 lysine 27 methylation in polycomb-group silencing. Science 298 (2002) 1039-1043
20. Varambally S., Dhanasekaran S.M., Zhou M., Barrette T.R., Kumar-Sinha C., Sanda M.G., et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419 (2002) 624-629
21. Kleer C.G., Cao Q., Varambally S., Shen R., Ota I., Tomlins S.A., et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 100 (2003) 11606-11611
22. Raaphorst F.M., Meijer C.J., Fieret E., Blokzijl T., Mommers E., et al. Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene. Neoplasia 5 (2003) 481-488
23. Matsukawa Y., Semba S., Kato H., Ito A., Yanagihara K., and Yokozaki H. Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Cancer Sci 97 (2006) 484-491
24. Sudo T., Utsunomiya T., Mimori K., et al. Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma. Brit J Cancer 92 (2005) 1754-1758
25. Arisan S., Buyuktuncer E.D., Palavan-Unsal N., Caskurlu T., Cakir O.O., and Ergenekon E. Increased expression of EZH2, a polycomb group protein, in bladder carcinoma. Urol Int 75 (2005) 252-257
26. Weikert S., Christoph F., Kollermann J., Muller M., Schrader M., et al. Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas. Int J Mol Med 16 (2005) 349-353
27. Sobin LH, Fleming ID. TNM classification of malignant tumors, 5th ed. Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997;80:1803-4.
28. Pindborg J.J., Reichart P.A., Smith C.J., and van der Waal I. Histological typing of cancer and precancer of the oral mucosa. 2nd ed. (1997), World Health Organization, Springer-Verlag, Berlin p. 24-40
29. Jakobsson P.A., Eneroth C.M., Killander D., Moberger G., and Martensson B. Histologic classification and grading of malignancy in carcinoma of the larynx. Acta Radiol Ther Phys Biol 12 (1973) 1-8
30. Kodani I., Osaki M., Shomori K., Araki K., Goto E., Ryoke K., et al. Minichromosome maintenance 2 expression is correlated with mode of invasion and prognosis in oral squamous cell carcinomas. J Oral Pathol Med 32 (2003) 468-474
31. Foster C.S., Falconer A., Dodson A.R., Norman A.R., Dennis N., Fletcher A., et al. Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome. Oncogene 23 (2004) 5871-5879
32. Breuer R.H., Snijders R.J., Smit E.F., Sutedja T.G., Sewalt R.G., Otte A.P., et al. Increased expression of the EZH2 polycomb group gene in BMI-1-positive neoplastic cells during bronchial carcinogenesis. Neoplasia 6 (2004) 736-743
33. Bracken A.P., Pasini D., Capra M., Prosperini E., Colli E., and Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 22 (2003) 5323-5335
34. Raman J.D., Mongan N.P., Tickoo S.K., Boorjian S.A., Scherr D.S., and Gudas L.J. Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder. Clin Cancer Res 11 (2005) 8570-8576
35. Ding L., Erdmann C., Chinnaiyan A.M., Merajver S.D., and Kleer C.G. Identification of EZH2 as a molecular marker for a precancerous state in morphologically normal breast tissues. Cancer Res 66 (2006) 4095-4099
36. Visser H.P., Gunster M.J., Kluin-Nelemans H.C., Monders E.M., Raaphorst F.M., Meijer C.J., et al. The polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma. Brit J Haematol 112 (2001) 950-958
37. Fukuyama T., Otsuka T., Shigematsu H., Arima F., Ohno Y., Iwasaki H., et al. Proliferative involvement of ENX-1, a putative human polycomb group gene, in haematopoietic cells. Brit J Haematol 108 (2002) 842-847
38. Kirmizis A., Bartley S.M., and Farnham P.J. Identification of the polycomb group protein SU(Z)12 as a potential molecular target for human cancer therapy. Mol Cancer Ther 2 (2003) 113-121